HK1209768A1 - Antibodies to tau - Google Patents

Antibodies to tau Download PDF

Info

Publication number
HK1209768A1
HK1209768A1 HK15110657.6A HK15110657A HK1209768A1 HK 1209768 A1 HK1209768 A1 HK 1209768A1 HK 15110657 A HK15110657 A HK 15110657A HK 1209768 A1 HK1209768 A1 HK 1209768A1
Authority
HK
Hong Kong
Prior art keywords
tau
antibodies
methods
relates
Prior art date
Application number
HK15110657.6A
Other languages
English (en)
Chinese (zh)
Inventor
David Holtzman
Hong Jiang
Marc Diamond
Najla KFOURY
Brandon HOLMES
Original Assignee
Washington University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University filed Critical Washington University
Publication of HK1209768A1 publication Critical patent/HK1209768A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
HK15110657.6A 2012-07-03 2013-07-03 Antibodies to tau HK1209768A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261667515P 2012-07-03 2012-07-03
US61/667,515 2012-07-03
US201261694989P 2012-08-30 2012-08-30
US61/694,989 2012-08-30
PCT/US2013/049333 WO2014008404A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Publications (1)

Publication Number Publication Date
HK1209768A1 true HK1209768A1 (en) 2016-04-08

Family

ID=49882495

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15110657.6A HK1209768A1 (en) 2012-07-03 2013-07-03 Antibodies to tau

Country Status (17)

Country Link
US (2) US9834596B2 (OSRAM)
EP (2) EP3838921A3 (OSRAM)
JP (3) JP6345655B2 (OSRAM)
KR (3) KR102494798B1 (OSRAM)
CN (2) CN104781278B (OSRAM)
AU (3) AU2013286680B2 (OSRAM)
BR (1) BR112014033116B1 (OSRAM)
CA (1) CA2877397A1 (OSRAM)
HK (1) HK1209768A1 (OSRAM)
IL (3) IL236409B (OSRAM)
IN (1) IN2015KN00007A (OSRAM)
MX (2) MX359555B (OSRAM)
MY (1) MY171473A (OSRAM)
NZ (2) NZ703423A (OSRAM)
RU (2) RU2668159C2 (OSRAM)
SG (3) SG10201913370PA (OSRAM)
WO (1) WO2014008404A1 (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3838921A3 (en) 2012-07-03 2021-09-01 Washington University Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) * 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
AU2015279086B2 (en) * 2014-06-26 2021-01-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3760235A1 (en) 2014-09-30 2021-01-06 Washington University Tau kinetic measurements
MA41451A (fr) * 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
PL3303386T3 (pl) 2015-06-05 2025-03-03 Genentech, Inc. Przeciwciała anty-tau i sposoby zastosowania
WO2017005734A1 (en) * 2015-07-06 2017-01-12 Ucb Biopharma Sprl Tau-binding antibodies
AU2016289753C1 (en) 2015-07-06 2021-08-05 UCB Biopharma SRL Tau-binding antibodies
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EP3334761B1 (en) * 2015-08-13 2023-07-19 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
CN105158483A (zh) * 2015-09-16 2015-12-16 北京九强生物技术股份有限公司 一种人肌钙蛋白i的超敏定量测定试剂盒及其检测方法
US10752679B2 (en) 2016-05-02 2020-08-25 Prothena Biosciences Limited Tau immunotherapy
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
MA56165A (fr) 2016-07-12 2022-04-20 H Lundbeck As Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
WO2018031361A2 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
TWI787219B (zh) 2016-12-07 2022-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
CN106749658B (zh) * 2016-12-15 2019-11-12 北京师范大学 抑制Tau蛋白聚集的抗体型分子伴侣
CN110072888B (zh) 2016-12-16 2023-07-18 H.隆德贝克有限公司 药剂、用途和方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
WO2018152359A1 (en) * 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
MX2019013045A (es) 2017-05-02 2020-02-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
MX2020009935A (es) * 2018-03-23 2021-01-08 Abbvie Deutschland Formulaciones acuosas y estables de anticuerpos anti-tau.
WO2019207164A1 (en) * 2018-04-27 2019-10-31 Ecole Polytechnique Federale De Lausanne (Epfl) A method for preparing phfs-like tau aggregates
JP2021530552A (ja) 2018-07-31 2021-11-11 イーライ リリー アンド カンパニー 併用療法
CN109613242A (zh) * 2018-11-01 2019-04-12 深圳天辰医疗科技有限公司 一种肌酸激酶同工酶检测试剂盒及其制备方法
AU2020231366A1 (en) 2019-03-03 2021-08-12 Prothena Biosciences Limited Antibodies recognizing tau
WO2020190932A1 (en) 2019-03-18 2020-09-24 Regeneron Pharmaceuticals, Inc. Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation
US11781131B2 (en) 2019-03-18 2023-10-10 Regeneron Pharmaceuticals, Inc. CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
CN110055280A (zh) * 2019-03-19 2019-07-26 深圳大学 一种稳定表达mCherry-tau的细胞系及其构建方法与应用
GB2600599B (en) * 2019-07-15 2025-05-21 Adel Inc Anti-Tau antibody and use thereof
CA3147548A1 (en) * 2019-08-13 2021-02-18 Randall Bateman Methods to detect mtbr tau isoforms and use thereof
IL292130A (en) 2019-10-09 2022-06-01 Bluerock Therapeutics Lp Cells with sustained transgene expression
KR20220110539A (ko) * 2019-12-04 2022-08-08 에이씨 이뮨 에스에이 치료 및 진단용 신규 분자
WO2022099314A1 (en) * 2020-11-09 2022-05-12 Meso Scale Technologies, Llc. Methods and kits for detecting tau
EP4271708A1 (en) 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
US20240150451A1 (en) 2021-03-26 2024-05-09 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
JP2024513172A (ja) 2021-03-26 2024-03-22 ヤンセン バイオテツク，インコーポレーテツド 対らせん状細線維タウに対するヒト化抗体及びその使用
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
JP2025530718A (ja) * 2022-08-23 2025-09-17 ワシントン・ユニバーシティ 抗タウｍｔｂｒ抗体、ならびにタウの切断された断片の検出方法およびその用途
WO2025018933A1 (en) * 2023-07-20 2025-01-23 Montoliu Gaya Laia P-tau immunoassay

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO884368L (no) 1987-10-02 1989-04-03 Du Pont Immunanalyse ved anvendelse av igg-innfangelsesantistoff og multippel, monoklonalt antistoffpaavisningssystem.
AU2414092A (en) 1991-08-01 1993-03-02 Paul H. Voorheis Diagnostic method for alzheimer's disease
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
CA2121599C (en) 1991-10-25 2007-04-10 Marc Mercken Monoclonal antibodies directed against the microtubule-associated protein tau
DE69233767D1 (de) 1991-12-06 2009-09-17 Max Planck Gesellschaft Verwendung von Protein-Kinasen zur Diagnose und Behandlung der Alzheimer-Krankheit
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AU710952B2 (en) 1994-07-29 1999-09-30 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US20020086009A1 (en) 1996-03-13 2002-07-04 Koichi Ishiguro Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
RU2238947C2 (ru) * 1998-07-14 2004-10-27 Янссен Фармацевтика Н.В. Нейротрофический фактор роста человека (эновин), кодирующая его выделенная молекула нуклеиновой кислоты, вектор (варианты), фармацевтическая композиция (варианты), антитело, способ обнаружения фактора роста, набор, способ идентификации агониста или антагониста (варианты)
JP4624559B2 (ja) 1998-09-08 2011-02-02 イノジェネティックス・ナムローゼ・フェンノートシャップ 初期ｃｎｓダメージのマーカーとしてのタウ
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US20020182660A1 (en) 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP3960855A1 (en) 2001-12-28 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Method for stabilizing proteins
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
DK1521774T3 (da) 2002-07-12 2008-10-27 Axon Neuroscience Trunkerede Tau-proteiner
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
WO2005018572A2 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
EP1848817B1 (en) 2005-02-19 2013-04-24 Peoplebio, Inc. Method for differentially detecting multimeric form from monomeric form of multimer-forming polypeptides
EP1940442A4 (en) 2005-08-04 2009-08-19 Einstein Coll Med Phosphorylation of tau by abl
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
MX2010011209A (es) 2008-04-24 2010-11-12 Squibb Bristol Myers Co Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer.
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
US20120064143A1 (en) * 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
US20110305706A1 (en) 2009-02-23 2011-12-15 Scott Thomas Brady Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL AIMING OF PATHOLOGICAL TAU PROTEINS
NZ598356A (en) * 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
CA2774173A1 (en) * 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
BR112012008381A2 (pt) 2009-09-24 2017-06-13 Inserm (Institut Nat De La Santé Et De La Rech Médicale) interação fkbp52-tau como novo alvo terapêutico para tratar os distúrbios neurológicos envolvendo disfunção da tau
US20130095492A1 (en) 2010-03-05 2013-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
RU2603078C2 (ru) 2010-10-07 2016-11-20 Ац Иммуне С.А. Фармацевтическая композиция
TR201812636T4 (tr) * 2010-10-11 2018-09-21 Biogen Int Neuroscience Gmbh İnsan anti-tau antikorları.
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
US9926353B2 (en) 2011-07-19 2018-03-27 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
BR112014006376B1 (pt) 2011-09-19 2021-07-27 Axon Neuroscience Se Anticorpo isolado que se liga a um ou mais epítopos tau, ácido nucleico, vetor, composição farmacêutica, artigo de fabricação, dispositivo médico, método in vitro para diagnosticar ou triar um indivíduo quanto à presença de doença de alzheimer ou de uma tauopatia relacionada e usos do referido anticorpo
CN108034005B (zh) 2011-10-07 2021-06-25 Ac免疫有限公司 识别Tau的磷酸化特异抗体
CA2853100A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
NZ626269A (en) 2011-12-20 2016-06-24 Janssen Biotech Inc Anti-phf-tau antibodies and their uses
WO2013151762A1 (en) 2012-04-05 2013-10-10 Ac Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
WO2013180238A1 (ja) 2012-05-31 2013-12-05 公立大学法人大阪市立大学 認知症治療剤又は予防剤
EP3838921A3 (en) 2012-07-03 2021-09-01 Washington University Antibodies to tau
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2885924C (en) 2012-08-21 2022-12-13 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
JP6324974B2 (ja) 2012-10-12 2018-05-23 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
WO2014089104A1 (en) 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
AU2014240063B2 (en) 2013-03-15 2019-04-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
RU2661111C2 (ru) 2013-03-15 2018-07-11 Ац Иммуне С.А. Антитела к тау и способы применения
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Also Published As

Publication number Publication date
JP2015530971A (ja) 2015-10-29
AU2013286680A1 (en) 2015-01-22
CN104781278B (zh) 2018-06-12
CN104781278A (zh) 2015-07-15
BR112014033116B1 (pt) 2021-12-21
US20180037641A1 (en) 2018-02-08
KR20150036346A (ko) 2015-04-07
IL277643A (en) 2020-11-30
AU2020223765A1 (en) 2020-09-17
CN108623682A (zh) 2018-10-09
NZ703423A (en) 2018-02-23
MX2014016024A (es) 2015-04-13
CA2877397A1 (en) 2014-01-09
JP6345655B2 (ja) 2018-06-20
EP2870176A4 (en) 2016-09-28
IL236409B (en) 2020-10-29
MX359555B (es) 2018-10-02
MX2022000026A (es) 2022-03-22
SG11201408626YA (en) 2015-03-30
RU2018132044A (ru) 2018-10-19
KR102494798B1 (ko) 2023-02-06
JP2018184398A (ja) 2018-11-22
US9834596B2 (en) 2017-12-05
SG10201913370PA (en) 2020-03-30
KR20200134339A (ko) 2020-12-01
SG10201708959WA (en) 2017-11-29
NZ739622A (en) 2020-01-31
AU2013286680B2 (en) 2018-07-05
IL289241A (en) 2022-02-01
EP2870176A1 (en) 2015-05-13
IL236409A0 (en) 2015-02-26
BR112014033116A2 (pt) 2018-03-06
KR20200013072A (ko) 2020-02-05
RU2015103228A (ru) 2016-08-20
WO2014008404A1 (en) 2014-01-09
MY171473A (en) 2019-10-15
RU2015103228A3 (OSRAM) 2018-03-05
AU2018229564A1 (en) 2018-10-04
JP2020125310A (ja) 2020-08-20
US20150183855A1 (en) 2015-07-02
EP3838921A3 (en) 2021-09-01
EP3838921A2 (en) 2021-06-23
IN2015KN00007A (OSRAM) 2015-07-31
RU2668159C2 (ru) 2018-09-26

Similar Documents

Publication Publication Date Title
HK1209768A1 (en) Antibodies to tau
WO2014189973A3 (en) Anti-transferrin receptor antibodies and methods of use
WO2014165771A3 (en) Anti-il-4 antibodies and bispecific antibodies and uses thereof
WO2014144865A3 (en) Anti-crth2 antibodies and their use
IL251697A0 (en) Antibodies against 3erbb and their uses
WO2014078268A8 (en) Anti-hemagglutinin antibodies and methods of use
EP3065776A4 (en) Novel anti-claudin antibodies and methods of use
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
EP3080607A4 (en) Novel anti-dpep3 antibodies and methods of use
ZA201704943B (en) Antibodies to tau and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
WO2013078217A3 (en) Anti-microbial peptides and methods of use thereof
WO2014001229A3 (en) Cell penetrating peptides & methods of identifying cell penetrating peptides
WO2014147640A3 (en) Process for the preparation of anagliptin
EP3060580A4 (en) Anti-podocalyxin antibodies and methods of using the same
IL236568A0 (en) Uses of alkylthiophene-rich compositions and methods of creating these compositions
WO2013181599A3 (en) Methods related to rituximab
WO2012166659A3 (en) Anti-emr1 antibodies
WO2014145302A3 (en) Synthesis of ent-progesterone and intermediates thereof
WO2013181572A3 (en) Methods related to panitumumab
WO2013181577A3 (en) Methods related to omalizumab
WO2014093305A3 (en) Micrornas and uses thereof